News & Updates

Current estimates of nonalcoholic fatty liver disease (NAFLD) incidence across the world show an increasing trend, with 4,613 new cases per 100,000 person-years, reveals a study.

Minimal monitoring is feasible in patients with active hepatitis C virus (HCV) infection treated with sofosbuvir/velpatasvir (SOF/VEL), with high rates of sustained virologic response (SVR) reported, including in patients with novel HCV subtypes, according to new data from the phase IV MINMON study presented at IDDF 2023.

The combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) with or without ribavirin demonstrates efficacy for the retreatment of patients with hepatitis C virus (HCV) infection in whom prior direct-acting antiviral (DAA) treatment has failed, a study in Egypt has shown.

Individuals with type 2 diabetes (T2D) may fare better with metabolic bariatric surgery, which confers more favourable long-term outcomes as compared with intensive medical and lifestyle management, based on the 7- and 12-year data from the ARMMS-T2D* trial.

In patients with hepatocellular carcinoma (HCC), most complications following transarterial chemoembolization (TACE) involve minor postembolization syndrome, reveals a study presented at EASL 2023. The incidence of major complications is high at 25 percent, with a 1.8-percent death rate.

Weight loss strategies do not only provide therapeutic alternatives for obesity but may also hold promise in the management of type 2 diabetes (T2D) and NAFLD*.

Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).